ライフサイエンスコーパス: included all patients who

1 ere based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation fo

2 The activity analysis included all patients who completed at least one full-schedul

3 This retrospective cohort included all patients who had HO bacteremia due to Escherichi

4 sessed in the modified intention-to-treat population, which included all patients who had surgery and completed at least

5 The primary, modified intention-to-treat analysis included all patients who had testable serum samples before a

6 juvant treatment, and in the per-protocol population, which included all patients who had tumour resection and received a

7 This analysis included all patients who met eligibility criteria on whom we

8 The pharmacokinetic-evaluable population included all patients who received all eight weekly daratumum

9 The safety population included all patients who received any amount of study drug.

10 efficacy analysis combined the SNF472 treatment groups and included all patients who received at least 1 dose of SNF472

11 analysed in the dose-limiting toxicity analysis set, which included all patients who received at least 90% of the first

12 ary endpoint was analysed using the per-protocol set, which included all patients who received at least one (partial or c

13 The safety population included all patients who received at least one daratumumab d

14 e done in the modified intention-to-treat population, which included all patients who received at least one day of treatm

15 Safety analyses included all patients who received at least one dose of any s

16 Safety analyses included all patients who received at least one dose of nivol

17 The safety analysis set included all patients who received at least one dose of rando

18 The safety population included all patients who received at least one dose of study

19 The safety and activity analysis set included all patients who received at least one dose of study

20 re analysed by intention to treat and the safety population included all patients who received at least one dose of study

21 acy analysis was by intention to treat, and safety analysis included all patients who received at least one dose of study

22 The safety population included all patients who received at least one dose of study

23 ll safety analyses were done based on the safety set, which included all patients who received at least one dose of study

24 pressure and HbA1c measured in the full analysis set, which included all patients who received at least one dose of study

25 The safety population included all patients who received at least one dose of study

26 Activity and safety analyses included all patients who received at least one dose of study

27 The safety evaluable population included all patients who received at least one dose of study

28 Safety analyses included all patients who received at least one dose of study

29 The efficacy analysis included all patients who received at least one dose of the r

30 Analyses included all patients who received at least one dose of the s

31 vestigator-assessed progression-free survival, and analyses included all patients who received at least one dose of the s

32 y endpoints were analysed in the safety analysis set, which included all patients who received at least one dose of tisle

33 The activity evaluable set included all patients who received at least one dose of trast

34 The safety analysis set included all patients who received at least one dose of trast

35 th a centrally confirmed BRCA mutation, and safety analyses included all patients who received at least one dose of velil

36 e done per protocol for all patients who commenced drug and included all patients who received at least one dose of venet

37 sessed in the modified intention-to-treat population, which included all patients who received neoadjuvant treatment, and

38 Safety analyses included all patients who received one or more dose of patisi

39 The safety analysis population included all patients who received study treatment irrespecti

40 Safety analyses included all patients who received the study drug (ADS-5102 o

41 The safety analysis included all patients who took at least one dose of study med

42 Analysis was done by intention-to-treat analysis, which included all patients who underwent end-of-treatment biopsy.

43 Primary analysis included all patients who underwent one of the assigned proce

44 Swedish nationwide population-based cohort study that included all patients who underwent primary isolated CABG bet

45 This retrospective observational study included all patients who underwent real-time ultrasound-guid

46 o underwent one of the assigned procedures; safety analysis included all patients who underwent surgical intervention (ca

47 dose of study drug, and the per-protocol population, which included all patients who used azathioprine or tocilizumab as

48 e done in the modified intention-to-treat population, which included all patients who were randomised and received at lea

49 yses used the modified intention-to-treat population, which included all patients who were randomly assigned, had a migra

50 dical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary